Lung Cancer

Researchers indicated that a lack of understanding of the mechanism and efficacy of PD-1/PD-L1 inhibitors is the major barrier for prescription of these inhibitors in Chinese tumor treatment-related departments.

Inconsistencies observed by researchers on these websites indicated that efforts are needed to improve website content and readability.

Delivering the PDA to clients of tobacco quit lines, researchers highlighted the importance of broader dissemination and greater effect of the intervention.

Researchers found that through inheritable changes of gene expression, chronic exposure to IL-1β can promote lung cancer metastasis, without altering DNA sequence.

According to researchers, when individuals quit smoking it not only stops further damage from accruing, but it also may lead to the reawakening of cells that were not damaged by tobacco carcinogens.

Oncoprex in combination with osimertinib received fast track designation from the FDA to treat patients with non-small cell lung cancer.

A recent study indicated that baseline BMI should be considered as a stratification factor in future immune checkpoint inhibitor therapy trials.

Although concurrent chemotherapy and radiation is considered standard care, treatment of locally advanced NSCLC continues to be challenging, leading researchers to search for patients who may benefit from the addition of cyclooxygenase 2 inhibitors.

The FDA accepted and granted priority review to the supplemental biologics license application for nivolumab in combination with ipilimumab for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer.

A 40-year-old woman presented with a productive cough and shortness of breath that limited her regular activities. Her past medical history was relevant for hypertension since 2016; it is well controlled and treated with enalapril 5 mg twice daily. She also revealed a past wood smoke exposure of 2 hours per day for 10 years during her childhood.

Data from the ongoing phase I/II ARROW clinical trial will be used to support a new drug application submission for pralsetinib to the FDA for the treatment of patients with RET fusion-positive non-small cell lung cancer.

The approach was created by the University of Michigan Rogel Cancer Center to limit variability and investigator bias.

These results could present an opportunity to broaden inclusion criteria on clinical trials and intensify chemoradiotherapy treatments.

In our lung cancer quiz, you'll get a chance to test your knowledge of the mortality risk among patients with lung cancer, and learn more about screening criteria to try reduce these rates.

Single dose radiotherapy may be as effective as 5 doses for patients with spinal canal compression from metastatic cancer.

To improve quality of life for patients with depression, researchers indicated it is crucial to provide referral and follow-up mental health care for patients with non-small cell lung cancer.

Integrated analyses showed entrectinib to be both effective and well tolerated in patients with rare ROS1 and NTRK gene fusions.

Patients with metastatic non-small cell lung cancer who harbor HER2-mutations may develop brain metastases more frequently during treatment.

The Food and Drug Administration approved the first generic for everolimus, which can provide a safe, effective, lower cost alternative to the brand-name drug it references.

The thoracic surgeon from NewYork-Presbyterian Hospital discusses a trial at the institution in which they give low-dose radiation therapy along with immunotherapy at the Annual New York Lung Cancers Symposium®.

Balazs Halmos, MD, MS, from Montefiore Albert Einstein Cancer Center, discussed advancements in treatment of metastatic non-small cell lung cancer at the Annual New York Lung Cancers Symposium®.

Ashish Saxena, MD, PhD, from Weill Cornell Medicine, discussed how immunotherapy may lead to an increase in overall survival of patients at the Annual New York Lung Cancers Symposium®.

The FDA approved atezolizumab in combination with chemotherapy for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations.

Kevin M. Sullivan, MD, from the Northwell Health Cancer Institute, discussed how the options for treatment of patients with lung cancer have expanded greatly at the Annual New York Lung Cancers Symposium®.

The FDA accepted a supplemental biologics license application and granted a priority review to durvalumab for the treatment of patients with previously untreated extensive-stage small cell lung cancer.

Takeda announced that their ongoing phase III ALTA-1L trial of brigatinib reduced the risk of disease progression or death in adults with advanced ALK-positive non-small cell lung cancer.

Predictive models demonstrated the ability to anticipate adverse opioid-related outcomes among cancer survivors.

The radiation oncologist from Memorial Sloan Kettering Cancer Center, discusses several ongoing trials combining immunotherapy and radiation at the 14th Annual New York Lung Cancers Symposium®.

Biomarker testing allows doctors to go beyond what’s under the microscope, helping to determine the best patient therapy.

The MSK expert discusses exciting advancements in the field of immunotherapy for treating lung cancer at the Annual New York Lung Cancers Symposium®.